COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,785 Articles (22,523 medRxiv, 8,262 bioRxiv)

Most recent first Previous |  Page 489: Articles 4881-4890  | Next

Modelling of outbreaks of SARS-CoV-2 Omicron variants after easing Dynamic Zero-COVID strategy in mainland China
Song, F., Bachmann, M. O.
10.1101/2022.12.22.22283841 — Posted: 2022-12-22
Wastewater monitoring of SARS-CoV-2 RNA at K-12 schools: Comparison to pooled clinical testing data
Kim, S., Boehm, A.
10.1101/2022.12.21.22283809 — Posted: 2022-12-22
To test or not to test? A new behavioral epidemiology framework for COVID-19
Sarkar, J.
10.1101/2022.12.22.22283830 — Posted: 2022-12-22
SARS-CoV-2 variant-specific differences in inhibiting the effects of the PKR-activated integrated stress response
Christ, W., Klingstrom, J., Tynell, J.
10.1101/2022.12.21.521388 — Posted: 2022-12-21
Altered somatic hypermutation patterns in COVID-19 patients classifies disease severity
Safra, M., Tamari, Z., Polak, P., Shiber, S., Matan, M., Karameh, H., Helviz, Y., Levy-Barda, A., Yahalom, V., Peretz, A., Ben-Chetrit, E., Brenner, B., Tuller, T., Gal-Tanamy, M., Yaari, G.
10.1101/2022.12.20.521139 — Posted: 2022-12-21
Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19
Geyer, C. E., Chen, H.-J., Bye, A. P., Manz, X. D., Guerra, D., Caniels, T. G., Bijl, T. P. L., Griffith, G. R., Hoepel, W., de Taeye, S. W., Veth, J., Vlaar, A. P. J., Amsterdam UMC COVID-19 Biobank, , Vidarsson, G., Bogaard, H. J., Aman, J., Gibbins, J. M., van Gils, M. J., Winther, M. P. J., den Dunnen, J.
10.1101/2022.12.20.521247 — Posted: 2022-12-21
Structure adaptation in Omicron SARS-CoV-2/hACE2:Biophysical origins of evolutionary driving forces
Hsiao, Y.-W., Taddese, T., Jimenez-Serratos, G., Bray, D. J., Crain, J.
10.1101/2022.12.20.521221 — Posted: 2022-12-21
Mechanism of LLPS of SARS-CoV-2 N protein
Song, J.
10.1101/2022.12.21.521431 — Posted: 2022-12-21
Stratification of hypertensive COVID-19 patients by quantitative NMR spectroscopy of serum metabolites, lipoproteins and inflammation markers
Kazenwadel, J., Berezhnoy, G., Cannet, C., Schaefer, H., Geisler, T., Rohlfing, A.-K., Gawaz, M., Merle, U., Trautwein, C.
10.1101/2022.12.20.22283729 — Posted: 2022-12-21
An approach to rapid distributed manufacturing of broad spectrum anti-viral griffithsin using cell-free systems to mitigate pandemics
Borhani, S. G., Levine, M. Z., Krumpe, L. H., Wilson, J., Hendrich, C., O'Keefe, B., Lo, D., Sittampalam, G., Godfrey, A., Lunsford, R. D., Mangalampalli, V., Tao, D., LeClair, C. A., Thole, A., Frey, D., Swartz, J. R., Rao, G.
10.1101/2022.12.19.521044 — Posted: 2022-12-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).